Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 132,312 shares changing hands.
Mateon Therapeutics Stock Performance
The company’s 50 day moving average is $0.03 and its 200 day moving average is $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Read More
- Five stocks we like better than Mateon Therapeutics
- What Does Downgrade Mean in Investing?
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Retail Stocks Investing, Explained
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- Election Stocks: How Elections Affect the Stock Market
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
